Objective-To investigate the impact of the clinical course of the primary HIV infection on the subsequent course of the infection.
Introduction
The clinical course of HIV infection with respect to factors that may predispose to or promote the development of symptoms is largely unknown. Several factors, including immunological and virological variables, have been reported to predict disease progression. '-7 Most of these variables seem to be consequences of infection or markers of the duration of infection rather than determinants of disease progression, and it should be emphasised that cofactors for disease progression
have not yet been found.
Most cohort studies so far have been performed with patients positive for HIV but without known time of seroconversion whereas longitudinal studies of those with known dates of seroconversion are scarce. We report on the clinical course of HIV infection in 86 men in whom the time of becoming positive for HIV antibody was known and relate disease progression to the clinical course of the primary infection.
Patients and methods
The study population was a group of 86 men seen at AIDS screening clinics in Copenhagen who became positive for HIV antibody within 12 months. All had had a negative test for HIV antibody followed by a confirmed positive test for HIV antibody. Seventy six were homosexual men, four were intravenous drug abusers, two were haemophiliacs, and four were heterosexuals. The median age was 30 (range 14-59) years.
Seroconversion was documented prospectively through repetitive HIV testing at the screening clinics in the period November 1984 to August 1988.8 Everyone had a physical examination and was given a standardised questionnaire by an interviewer that sought information on illnesses within the previous three months. 9 The result of the antibody test was not known at the time of the interview. The We also compared changes in the absolute number of CD4 lymphocytes after seroconversion (fig 1) . At baseline and at six month follow up there was no significant difference in the CD4 cell count between the groups, but during the second year after seroconversion the CD4 cell count decreased significantly in the group with longlasting illness in association with seroconversion whereas it remained stable in those 11 (seven with oral thrush, one with hairy leucoplakia, three with herpes zoster), and AIDS associated opportunistic infections in five (four with Pneumocystis carinii pneumonia, one with oesophageal candidiasis). The overall actuarial progression rate to group IV was 35% (95% confidence interval 13% to 58%) at three years.
Disease progression was significantly associated with the duration of symptoms during seroconversion (p<0001) (fig 2) . The three year progression rate was 78% (52% to 100%) for subjects with longlasting tDuring four weeks after treatment with iron was started.
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,ug/l and transferrin saturations >30% before treatment). Each of the five patients had an initial rise in haemoglobin concentration, which was not sustained; they were then given iron dextran intravenously (Imferon; 50 mg elemental iron/ml) 1 ml twice weekly during the last hour of dialysis. The mean weekly rise in haemoglobin concentration during the four weeks before intravenous treatment with iron was 2-0 g/l; this rose to 5 3 g/l after the treatment was started (p<0005, paired t test), indicating more effective erythropoiesis even though the dose of erythropoietin was the same (table) . Four of the patients had normal serum ferritin concentrations immediately before treatment with iron, suggesting adequate stores of iron in marrow; the remaining patient had a concentration at the lower limit of the normal range. In contrast, all five patients had low transferrin saturations (<20%).
Comment
Our data show a retarded response of haemoglobin concentration to erythropoietin, which was corrected by giving iron intravenously. Eschbach et al also reported on a patient in whom the response of the packed cell volume declined in the presence of an ample serum ferritin concentration (518 [tg/l) but low transferrin saturation (13%); this patient also responded to intravenous treatment with iron dextran. ' Erythropoietin seems to stimulate erythropoiesis to such an extent that the demand for iron can exceed the body's ability to release it from stores. This may lead to a functional iron deficiency, which can occur when serum ferritin concentrations are normal and iron can be detected in the marrow by staining.
Previous studies have suggested that stores of iron are adequate for erythropoiesis only if for every 50 g/l rise in haemoglobin concentration a serum ferritin concentration of ¢ 100 jig/l is present.2 Patients who are particularly likely to develop functional iron deficiency, therefore, are those with serum ferritin
